C-Abl as a modulator of p53

Biochemical and Biophysical Research Communications

Volumn 331, Issue 3, 2005, Pages 737-749

  Levav Cohen, Yaara ^a   Goldberg, Zehavit ^a   Zuckerman, Valentina ^a   Grossman, Tamar ^a   Haupt, Sue ^a   Haupt, Ygal ^a  

^a HEBREW UNIVERSITY   (Israel)

Author keywords

Bcr Abl; c Abl; Degradation; HPV E6; Mdm2; Mdmx; p53; Phosphorylation; Ubiquitination

Indexed keywords

ABELSON KINASE; ANTILEUKEMIC AGENT; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; CISPLATIN; CYTARABINE; HUMAN PAPILLOMA VIRUS E6 UBIQUINATION LIGASE E6 ASSOCIATED PROTEIN COMPLEX; IMATINIB; LEPTOMYCIN B; LIGASE; MESYLIC ACID METHYL ESTER; MITOMYCIN C; PHOSPHOTRANSFERASE INHIBITOR; PROTEASOME INHIBITOR; PROTEIN E6; PROTEIN INHIBITOR; PROTEIN MDM2; PROTEIN MDMX; PROTEIN P53; PROTEIN P53 INHIBITOR; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER INHIBITION; CARCINOGENICITY; CHRONIC MYELOID LEUKEMIA; DNA DAMAGE; ENZYME ACTIVITY; GROWTH INHIBITION; HUMAN; HUMAN PAPILLOMAVIRUS E6; HUMAN PAPILLOMAVIRUS TYPE 6; MULTIMODALITY CANCER THERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REVIEW; WART VIRUS;

EID: 18144408056     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbrc.2005.03.152     Document Type: Review

References (133)

1. R.V. Sionov, and Y. Haupt The cellular response to p53: the decision between life and death Oncogene 18 1999 6145 6157
2. D.W. Meek The p53 response to DNA damage DNA Repair (Amst) 3 2004 1049 1056
3. B. Vogelstein, D. Lane, and A.J. Levine Surfing the p53 network Nature 408 2000 307 310
4. C.A. Schmitt, J.S. Fridman, M. Yang, E. Baranov, R.M. Hoffman, and S.W. Lowe Dissecting p53 tumor suppressor functions in vivo Cancer Cell 1 2002 289 298
5. S. Haupt, M. Berger, Z. Goldberg, and Y. Haupt Apoptosis-the p53 network J. Cell Sci. 116 2003 4077 4085
6. A. Villunger, E.M. Michalak, L. Coultas, F. Mullauer, G. Bock, M.J. Ausserlechner, J.M. Adams, and A. Strasser p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa Science 302 2003 1036 1038
7. Y. Haupt, S. Rowan, E. Shaulian, K.H. Vousden, and M. Oren Induction of apoptosis in HeLa cells by trans-activation-deficient p53 Genes Dev. 9 1995 2170 2183
8. S. Erster, M. Mihara, R.H. Kim, O. Petrenko, and U.M. Moll In vivo mitochondrial p53 translocation triggers a rapid first wave of cell death in response to DNA damage that can precede p53 target gene activation Mol. Cell Biol. 24 2004 6728 6741
9. R. Montes de Oca Luna, D.S. Wagner, and G. Lozano Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53 Nature 378 1995 203 206
10. S.N. Jones, A.E. Roe, L.A. Donehower, and A. Bradley Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53 Nature 378 1995 206 208
11. J. Momand, H.H. Wu, and G. Dasgupta MDM2-master regulator of the p53 tumor suppressor protein Gene 242 2000 15 29
12. J.D. Oliner, K.W. Kinzler, P.S. Meltzer, D.L. George, and B. Vogelstein Amplification of a gene encoding a p53-associated protein in human sarcomas Nature 358 1992 80 83
13. D. Michael, and M. Oren The p53-Mdm2 module and the ubiquitin system Semin. Cancer Biol. 13 2003 49 58
14. M. Li, C.L. Brooks, F. Wu-Baer, D. Chen, R. Baer, and W. Gu Mono- versus polyubiquitination: differential control of p53 fate by Mdm2 Science 302 2003 1972 1975
15. D.P. Xirodimas, M.K. Saville, J.C. Bourdon, R.T. Hay, and D.P. Lane Mdm2-mediated NEDD8 conjugation of p53 inhibits its transcriptional activity Cell 118 2004 83 97
16. S.R. Grossman, M.E. Deato, C. Brignone, H.M. Chan, A.L. Kung, H. Tagami, Y. Nakatani, and D.M. Livingston Polyubiquitination of p53 by a ubiquitin ligase activity of p300 Science 300 2003 342 344
17. M. Koegl, T. Hoppe, S. Schlenker, H.D. Ulrich, T.U. Mayer, and S. Jentsch A novel ubiquitination factor, E4, is involved in multiubiquitin chain assembly Cell 96 1999 635 644
18. D. Dornan, I. Wertz, H. Shimizu, D. Arnott, G.D. Frantz, P. Dowd, K. O'Rourke, H. Koeppen, and V.M. Dixit The ubiquitin ligase COP1 is a critical negative regulator of p53 Nature 429 2004 86 92
19. R.P. Leng, Y. Lin, W. Ma, H. Wu, B. Lemmers, S. Chung, J.M. Parant, G. Lozano, R. Hakem, and S. Benchimol Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation Cell 112 2003 779 791
20. A. Shvarts, W.T. Steegenga, N. Riteco, T. van Laar, P. Dekker, M. Bazuine, R.C. van Ham, W. van der Houven van Oordt, G. Hateboer, A.J. van der Eb, and A.G. Jochemsen MDMX: a novel p53-binding protein with some functional properties of MDM2 EMBO J. 15 1996 5349 5357
21. A. Shvarts, M. Bazuine, P. Dekker, Y.F. Ramos, W.T. Steegenga, G. Merckx, R.C. van Ham, W. van der Houven van Oordt, A.J. van der Eb, and A.G. Jochemsen Isolation and identification of the human homolog of a new p53-binding protein, Mdmx Genomics 43 1997 34 42
22. S. Tanimura, S. Ohtsuka, K. Mitsui, K. Shirouzu, A. Yoshimura, and M. Ohtsubo MDM2 interacts with MDMX through their RING finger domains FEBS Lett. 447 1999 5 9
23. D.A. Sharp, S.A. Kratowicz, M.J. Sank, and D.L. George Stabilization of the MDM2 oncoprotein by interaction with the structurally related MDMX protein J. Biol. Chem. 274 1999 38189 38196
24. J. Parant, A. Chavez-Reyes, N.A. Little, W. Yan, V. Reinke, A.G. Jochemsen, and G. Lozano Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53 Nat. Genet. 29 2001 92 95
25. D. Migliorini, E.L. Denchi, D. Danovi, A. Jochemsen, M. Capillo, A. Gobbi, K. Helin, P.G. Pelicci, and J.C. Marine Mdm4 (Mdmx) regulates p53-induced growth arrest and neuronal cell death during early embryonic mouse development Mol. Cell Biol. 22 2002 5527 5538
26. R.A. Finch, D.B. Donoviel, D. Potter, M. Shi, A. Fan, D.D. Freed, C.Y. Wang, B.P. Zambrowicz, R. Ramirez-Solis, A.T. Sands, and N. Zhang mdmx is a negative regulator of p53 activity in vivo Cancer Res. 62 2002 3221 3225
27. D. Danovi, E. Meulmeester, D. Pasini, D. Migliorini, M. Capra, R. Frenk, P. de Graaf, S. Francoz, P. Gasparini, A. Gobbi, K. Helin, P.G. Pelicci, A.G. Jochemsen, and J.C. Marine Amplification of Mdmx (or Mdm4) directly contributes to tumor formation by inhibiting p53 tumor suppressor activity Mol. Cell Biol. 24 2004 5835 5843
28. Y.F. Ramos, R. Stad, J. Attema, L.T. Peltenburg, A.J. van der Eb, and A.G. Jochemsen Aberrant expression of HDMX proteins in tumor cells correlates with wild-type p53 Cancer Res. 61 2001 1839 1842
29. M.J. Riemenschneider, R. Buschges, M. Wolter, J. Reifenberger, J. Bostrom, J.A. Kraus, U. Schlegel, and G. Reifenberger Amplification and overexpression of the MDM4 (MDMX) gene from 1q32 in a subset of malignant gliomas without TP53 mutation or MDM2 amplification Cancer Res. 59 1999 6091 6096
30. M.J. Riemenschneider, C.B. Knobbe, and G. Reifenberger Refined mapping of 1q32 amplicons in malignant gliomas confirms MDM4 as the main amplification target Int. J. Cancer 104 2003 752 757
31. V. Bottger, A. Bottger, C. Garcia-Echeverria, Y.F. Ramos, A.J. van der Eb, A.G. Jochemsen, and D.P. Lane Comparative study of the p53-mdm2 and p53-MDMX interfaces Oncogene 18 1999 189 199
32. J.C. Marine, and A.G. Jochemsen Mdmx and Mdm2: brothers in arms? Cell Cycle 3 2004 900 904
33. R. Rallapalli, G. Strachan, R.S. Tuan, and D.J. Hall Identification of a domain within MDMX-S that is responsible for its high affinity interaction with p53 and high-level expression in mammalian cells J. Cell Biochem. 89 2003 563 575
34. P. Sabbatini, and F. McCormick MDMX inhibits the p300/CBP-mediated acetylation of p53 DNA Cell Biol. 21 2002 519 525
35. M.W. Jackson, and S.J. Berberich MdmX protects p53 from Mdm2-mediated degradation Mol. Cell Biol. 20 2000 1001 1007
36. R. Stad, Y.F. Ramos, N. Little, S. Grivell, J. Attema, A.J. van Der Eb, and A.G. Jochemsen Hdmx stabilizes Mdm2 and p53 J. Biol. Chem. 275 2000 28039 28044
37. R. Stad, N.A. Little, D.P. Xirodimas, R. Frenk, A.J. van der Eb, D.P. Lane, M.K. Saville, and A.G. Jochemsen Mdmx stabilizes p53 and Mdm2 via two distinct mechanisms EMBO Rep. 2 2001 1029 1034
38. L.K. Linares, A. Hengstermann, A. Ciechanover, S. Muller, and M. Scheffner HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53 Proc. Natl. Acad. Sci. USA 100 2003 12009 12014
39. M. Ghosh, K. Huang, and S.J. Berberich Overexpression of Mdm2 and MdmX fusion proteins alters p53 mediated transactivation, ubiquitination, and degradation Biochemistry 42 2003 2291 2299
40. F. Mancini, F. Gentiletti, M. D'Angelo, S. Giglio, S. Nanni, C. D'Angelo, A. Farsetti, G. Citro, A. Sacchi, A. Pontecorvi, and F. Moretti MDM4 (MDMX) overexpression enhances stabilization of stress-induced p53 and promotes apoptosis J. Biol. Chem. 279 2004 8169 8180
41. F. Gentiletti, F. Mancini, M. D'Angelo, A. Sacchi, A. Pontecorvi, A.G. Jochemsen, and F. Moretti MDMX stability is regulated by p53-induced caspase cleavage in NIH3T3 mouse fibroblasts Oncogene 21 2002 867 877
42. J. Gu, H. Kawai, L. Nie, H. Kitao, D. Wiederschain, A.G. Jochemsen, J. Parant, G. Lozano, and Z.M. Yuan Mutual dependence of MDM2 and MDMX in their functional inactivation of p53 J. Biol. Chem. 277 2002 19251 19254
43. C. Li, L. Chen, and J. Chen DNA damage induces MDMX nuclear translocation by p53-dependent and -independent mechanisms Mol. Cell Biol. 22 2002 7562 7571
44. D. Migliorini, D. Danovi, E. Colombo, R. Carbone, P.G. Pelicci, and J.C. Marine Hdmx recruitment into the nucleus by Hdm2 is essential for its ability to regulate p53 stability and transactivation J. Biol. Chem. 277 2002 7318 7323
45. P. de Graaf, N.A. Little, Y.F. Ramos, E. Meulmeester, S.J. Letteboer, and A.G. Jochemsen Hdmx protein stability is regulated by the ubiquitin ligase activity of Mdm2 J. Biol. Chem. 278 2003 38315 38324
46. H. Kawai, D. Wiederschain, H. Kitao, J. Stuart, K.K. Tsai, and Z.M. Yuan DNA damage-induced MDMX degradation is mediated by MDM2 J. Biol. Chem. 278 2003 45946 45953
47. S. Haupt, and Y. Haupt Manipulation of the tumor suppressor p53 for potentiating cancer therapy Semin. Cancer Biol. 14 2004 244 252
48. Z. Goldberg, Y. Levav, S. Krichevsky, E. Fibach, and Y. Haupt Treatment of chronic myeloid leukemia cells with Imatinib (STI571) impairs p53 accumulation in response to DNA damage Cell Cycle 3 2004 80 87
49. P. Zacchi, M. Gostissa, T. Uchida, C. Salvagno, F. Avolio, S. Volinia, Z. Ronai, G. Blandino, C. Schneider, and G. Del Sal The prolyl isomerase Pin1 reveals a mechanism to control p53 functions after genotoxic insults Nature 419 2002 853 857
50. J. Ahn, M. Urist, and C. Prives The Chk2 protein kinase DNA Repair (Amst) 3 2004 1039 1047
51. N.H. Chehab, A. Malikzay, M. Appel, and T.D. Halazonetis Chk2/hCds1 functions as a DNA damage checkpoint in G(1) by stabilizing p53 Genes Dev. 14 2000 278 288
52. A. Hirao, Y.Y. Kong, S. Matsuoka, A. Wakeham, J. Ruland, H. Yoshida, D. Liu, S.J. Elledge, and T.W. Mak DNA damage-induced activation of p53 by the checkpoint kinase Chk2 Science 287 2000 1824 1827
53. S.Y. Shieh, J. Ahn, K. Tamai, Y. Taya, and C. Prives The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites Genes Dev. 14 2000 289 300
54. Q.B. She, W.Y. Ma, and Z. Dong Role of MAP kinases in UVB-induced phosphorylation of p53 at serine 20 Oncogene 21 2002 1580 1589
55. S. Xie, H. Wu, Q. Wang, J. Kunicki, R.O. Thomas, R.E. Hollingsworth, J. Cogswell, and W. Dai Genotoxic stress-induced activation of Plk3 is partly mediated by Chk2 Cell Cycle 1 2002 424 429
56. N.H. Chehab, A. Malikzay, E.S. Stavridi, and T.D. Halazonetis Phosphorylation of Ser-20 mediates stabilization of human p53 in response to DNA damage Proc. Natl. Acad. Sci. USA 96 1999 13777 13782
57. T. Unger, T. Juven-Gershon, E. Moallem, M. Berger, R. Vogt Sionov, G. Lozano, M. Oren, and Y. Haupt Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2 EMBO J. 18 1999 1805 1814
58. J. Bartek, J. Falck, and J. Lukas CHK2 kinase-a busy messenger Nat. Rev. Mol. Cell Biol. 2 2001 877 886
59. M. Li, D. Chen, A. Shiloh, J. Luo, A.Y. Nikolaev, J. Qin, and W. Gu Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization Nature 416 2002 648 653
60. M. Li, C.L. Brooks, N. Kon, and W. Gu A dynamic role of HAUSP in the p53-Mdm2 pathway Mol. Cell 13 2004 879 886
61. J.M. Cummins, and B. Vogelstein HAUSP is required for p53 destabilization Cell Cycle 3 2004 689 692
62. M. Hu, P. Li, M. Li, W. Li, T. Yao, J.W. Wu, W. Gu, R.E. Cohen, and Y. Shi Crystal structure of a UBP-family deubiquitinating enzyme in isolation and in complex with ubiquitin aldehyde Cell 111 2002 1041 1054
63. C.L. Brooks, and W. Gu Dynamics in the p53-Mdm2 ubiquitination pathway Cell Cycle 3 2004 895 899
64. J. Zhu, and J.Y. Wang Death by Abl: a matter of location Curr. Top. Dev. Biol. 59 2004 165 192
65. B. Nagar, O. Hantschel, M.A. Young, K. Scheffzek, D. Veach, W. Bornmann, B. Clarkson, G. Superti-Furga, and J. Kuriyan Structural basis for the autoinhibition of c-Abl tyrosine kinase Cell 112 2003 859 871
66. J.Y. Wang Controlling Abl: auto-inhibition and co-inhibition? Nat. Cell Biol. 6 2004 3 7
67. Y. Shaul c-Abl: activation and nuclear targets Cell Death Differ. 7 2000 10 16
68. R. Agami, G. Blandino, M. Oren, and Y. Shaul Interaction of c-Abl and p73alpha and their collaboration to induce apoptosis Nature 399 1999 809 813
69. Z.M. Yuan, H. Shioya, T. Ishiko, X. Sun, J. Gu, Y.Y. Huang, H. Lu, S. Kharbanda, R. Weichselbaum, and D. Kufe p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage Nature 399 1999 814 817
70. K.K. Tsai, and Z.M. Yuan c-Abl stabilizes p73 by a phosphorylation- augmented interaction Cancer Res. 63 2003 3418 3424
71. B. Wang, E.A. Golemis, and G.D. Kruh ArgBP2, a multiple Src homology 3 domain-containing, Arg/Abl-interacting protein, is phosphorylated in v-Abl-transformed cells and localized in stress fibers and cardiocyte Z-disks J. Biol. Chem. 272 1997 17542 17550
72. A. Goga, X. Liu, T.M. Hambuch, K. Senechal, E. Major, A.J. Berk, O.N. Witte, and C.L. Sawyers p53 dependent growth suppression by the c-Abl nuclear tyrosine kinase Oncogene 11 1995 791 799
73. S.E. Hernandez, M. Krishnaswami, A.L. Miller, and A.J. Koleske How do Abl family kinases regulate cell shape and movement? Trends Cell Biol. 14 2004 36 44
74. P. Soubeyran, A. Barac, I. Szymkiewicz, and I. Dikic Cbl-ArgBP2 complex mediates ubiquitination and degradation of c-Abl Biochem. J. 370 2003 29 34
75. Y.E. Whang, C. Tran, C. Henderson, R.G. Syljuasen, N. Rozengurt, W.H. McBride, and C.L. Sawyers c-Abl is required for development and optimal cell proliferation in the context of p53 deficiency Proc. Natl. Acad. Sci. USA 97 2000 5486 5491
76. S. Kharbanda, R. Ren, P. Pandey, T.D. Shafman, S.M. Feller, R.R. Weichselbaum, and D.W. Kufe Activation of the c-Abl tyrosine kinase in the stress response to DNA-damaging agents Nature 376 1995 785 788
77. Z.G. Liu, R. Baskaran, E.T. Lea-Chou, L.D. Wood, Y. Chen, M. Karin, and J.Y. Wang Three distinct signalling responses by murine fibroblasts to genotoxic stress Nature 384 1996 273 276
78. Y. Huang, Z.M. Yuan, T. Ishiko, S. Nakada, T. Utsugisawa, T. Kato, S. Kharbanda, and D.W. Kufe Pro-apoptotic effect of the c-Abl tyrosine kinase in the cellular response to 1-beta-D-arabinofuranosylcytosine Oncogene 15 1997 1947 1952
79. Z.M. Yuan, Y. Huang, Y. Whang, C. Sawyers, R. Weichselbaum, S. Kharbanda, and D. Kufe Role for c-Abl tyrosine kinase in growth arrest response to DNA damage Nature 382 1996 272 274
80. J.Y. Wang Regulation of cell death by the Abl tyrosine kinase Oncogene 19 2000 5643 5650
81. R. Baskaran, L.D. Wood, L.L. Whitaker, C.E. Canman, S.E. Morgan, Y. Xu, C. Barlow, D. Baltimore, A. Wynshaw-Boris, M.B. Kastan, and J.Y. Wang Ataxia telangiectasia mutant protein activates c-Abl tyrosine kinase in response to ionizing radiation Nature 387 1997 516 519
82. T. Shafman, K.K. Khanna, P. Kedar, K. Spring, S. Kozlov, T. Yen, K. Hobson, M. Gatei, N. Zhang, D. Watters, M. Egerton, Y. Shiloh, S. Kharbanda, D. Kufe, and M.F. Lavin Interaction between ATM protein and c-Abl in response to DNA damage Nature 387 1997 520 523
83. S.T. Wen, P.K. Jackson, and R.A. Van Etten The cytostatic function of c-Abl is controlled by multiple nuclear localization signals and requires the p53 and Rb tumor suppressor gene products EMBO J. 15 1996 1583 1595
84. Z.M. Yuan, Y. Huang, M.M. Fan, C. Sawyers, S. Kharbanda, and D. Kufe Genotoxic drugs induce interaction of the c-Abl tyrosine kinase and the tumor suppressor protein p53 J. Biol. Chem. 271 1996 26457 26460
85. J.G. Gong, A. Costanzo, H.Q. Yang, G. Melino, W.G. Kaelin Jr., M. Levrero, and J.Y. Wang The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage Nature 399 1999 806 809
86. Z.M. Yuan, Y. Huang, T. Ishiko, S. Kharbanda, R. Weichselbaum, and D. Kufe Regulation of DNA damage-induced apoptosis by the c-Abl tyrosine kinase Proc. Natl. Acad. Sci. USA 94 1997 1437 1440
87. R.V. Sionov, E. Moallem, M. Berger, A. Kazaz, O. Gerlitz, Y. Ben-Neriah, M. Oren, and Y. Haupt c-Abl neutralizes the inhibitory effect of Mdm2 on p53 J. Biol. Chem. 274 1999 8371 8374
88. G. Blandino, and M. Dobbelstein p73 and p63: why do we still need them? Cell Cycle 3 2004 886 894
89. E.R. Flores, K.Y. Tsai, D. Crowley, S. Sengupta, A. Yang, F. McKeon, and T. Jacks p63 and p73 are required for p53-dependent apoptosis in response to DNA damage Nature 416 2002 560 564
90. M.E. Murphy, J.I. Leu, and D.L. George p53 Moves to mitochondria: a turn on the path to apoptosis Cell Cycle 3 2004 836 839
91. J.E. Chipuk, and D.R. Green Cytoplasmic p53: bax and forward Cell Cycle 3 2004 429 431
92. S. Kumar, A. Bharti, N.C. Mishra, D. Raina, S. Kharbanda, S. Saxena, and D. Kufe Targeting of the c-Abl tyrosine kinase to mitochondria in the necrotic cell death response to oxidative stress J. Biol. Chem. 276 2001 17281 17285
93. Y. Ito, P. Pandey, N. Mishra, S. Kumar, N. Narula, S. Kharbanda, S. Saxena, and D. Kufe Targeting of the c-Abl tyrosine kinase to mitochondria in endoplasmic reticulum stress-induced apoptosis Mol. Cell Biol. 21 2001 6233 6242
94. R.V. Sionov, S. Coen, Z. Goldberg, M. Berger, B. Bercovich, Y. Ben-Neriah, A. Ciechanover, and Y. Haupt c-Abl regulates p53 levels under normal and stress conditions by preventing its nuclear export and ubiquitination Mol. Cell Biol. 21 2001 5869 5878
95. Y. Nie, H.H. Li, C.M. Bula, and X. Liu Stimulation of p53 DNA binding by c-Abl requires the p53 C terminus and tetramerization Mol. Cell Biol. 20 2000 741 748
96. R.L. Weinberg, S.M. Freund, D.B. Veprintsev, M. Bycroft, and A.R. Fersht Regulation of DNA binding of p53 by its C-terminal domain J. Mol. Biol. 342 2004 801 811
97. M.S. Rodriguez, J.M. Desterro, S. Lain, D.P. Lane, and R.T. Hay Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation Mol. Cell Biol. 20 2000 8458 8467
98. M. Ben-Yehoyada, I. Ben-Dor, and Y. Shaul c-Abl tyrosine kinase selectively regulates p73 nuclear matrix association J. Biol. Chem. 278 2003 34475 34482
99. T. Kamijo, J.D. Weber, G. Zambetti, F. Zindy, M.F. Roussel, and C.J. Sherr Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2 Proc. Natl. Acad. Sci. USA 95 1998 8292 8297
100. C.L. Sawyers, J. McLaughlin, A. Goga, M. Havlik, and O. Witte The nuclear tyrosine kinase c-Abl negatively regulates cell growth Cell 77 1994 121 131
101. Z. Goldberg, R. Vogt Sionov, M. Berger, Y. Zwang, R. Perets, R.A. Van Etten, M. Oren, Y. Taya, and Y. Haupt Tyrosine phosphorylation of Mdm2 by c-Abl: implications for p53 regulation EMBO J. 21 2002 3715 3727
102. R. Khosravi, R. Maya, T. Gottlieb, M. Oren, Y. Shiloh, and D. Shkedy Rapid ATM-dependent phosphorylation of MDM2 precedes p53 accumulation in response to DNA damage Proc. Natl. Acad. Sci. USA 96 1999 14973 14977
103. R. Maya, M. Balass, S.T. Kim, D. Shkedy, J.F. Leal, O. Shifman, M. Moas, T. Buschmann, Z. Ronai, Y. Shiloh, M.B. Kastan, E. Katzir, and M. Oren ATM-dependent phosphorylation of Mdm2 on serine 395: role in p53 activation by DNA damage Genes Dev. 15 2001 1067 1077
104. M.S. Longworth, and L.A. Laimins Pathogenesis of human papillomaviruses in differentiating epithelia Microbiol. Mol. Biol. Rev. 68 2004 362 372
105. M. Scheffner, J.M. Huibregtse, R.D. Vierstra, and P.M. Howley The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53 Cell 75 1993 495 505
106. X. Li, and P. Coffino High-risk human papillomavirus E6 protein has two distinct binding sites within p53, of which only one determines degradation J. Virol. 70 1996 4509 4516
107. J. Gu, R.M. Rubin, and Z.M. Yuan A sequence element of p53 that determines its susceptibility to viral oncoprotein-targeted degradation Oncogene 20 2001 3519 3527
108. D.A. Freedman, and A.J. Levine Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6 Mol. Cell Biol. 18 1998 7288 7293
109. H. Huang, S.Y. Huang, T.T. Chen, J.C. Chen, C.L. Chiou, and T.M. Huang Cisplatin restores p53 function and enhances the radiosensitivity in HPV16 E6 containing SiHa cells J. Cell Biochem. 91 2004 756 765
110. K. Butz, L. Shahabeddin, C. Geisen, D. Spitkovsky, A. Ullmann, and F. Hoppe-Seyler Functional p53 protein in human papillomavirus-positive cancer cells Oncogene 10 1995 927 936
111. J. Wesierska-Gadek, D. Schloffer, V. Kotala, and M. Horky Escape of p53 protein from E6-mediated degradation in HeLa cells after cisplatin therapy Int. J. Cancer 101 2002 128 136
112. P.J. Shteper, and D. Ben-Yehuda Molecular evolution of chronic myeloid leukaemia Semin. Cancer Biol. 11 2001 313 323
113. S. Wong, and O.N. Witte The BCR-ABL story: bench to bedside and back Annu. Rev. Immunol. 22 2004 247 306
114. J.R. McWhirter, D.L. Galasso, and J.Y. Wang A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins Mol. Cell Biol. 13 1993 7587 7595
115. A.M. Pendergast, L.A. Quilliam, L.D. Cripe, C.H. Bassing, Z. Dai, N. Li, A. Batzer, K.M. Rabun, C.J. Der, and J. Schlessinger BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein Cell 75 1993 175 185
116. Y. He, J.A. Wertheim, L. Xu, J.P. Miller, F.G. Karnell, J.K. Choi, R. Ren, and W.S. Pear The coiled-coil domain and Tyr177 of bcr are required to induce a murine chronic myelogenous leukemia-like disease by bcr/abl Blood 99 2002 2957 2968
117. B.J. Druker, S.G. O'Brien, J. Cortes, and J. Radich Chronic myelogenous leukemia Hematology (Am. Soc. Hematol. Educ. Program) 2002 111 135
118. H. Ahuja, M. Bar-Eli, Z. Arlin, S. Advani, S.L. Allen, J. Goldman, D. Snyder, A. Foti, and M. Cline The spectrum of molecular alterations in the evolution of chronic myelocytic leukemia J. Clin. Invest. 87 1991 2042 2047
119. E. Feinstein, G. Cimino, R.P. Gale, G. Alimena, R. Berthier, K. Kishi, J. Goldman, A. Zaccaria, A. Berrebi, and E. Canaani p53 in chronic myelogenous leukemia in acute phase Proc. Natl. Acad. Sci. USA 88 1991 6293 6297
120. F. Lanza, and S. Bi Role of p53 in leukemogenesis of chronic myeloid leukemia Stem Cells 13 1995 445 452
121. K. Keeshan, K.I. Mills, T.G. Cotter, and S.L. McKenna Elevated Bcr-Abl expression levels are sufficient for a haematopoietic cell line to acquire a drug-resistant phenotype Leukemia 15 2001 1823 1833
122. T. Stoklosa, A. Slupianek, M. Datta, M. Nieborowska-Skorska, M.O. Nowicki, M. Koptyra, and T. Skorski BCR/ABL recruits p53 tumor suppressor protein to induce drug resistance Cell Cycle 3 2004 93 102
123. J. Bartek, and J. Lukas Chk1 and Chk2 kinases in checkpoint control and cancer Cancer Cell 3 2003 421 429
124. F. Cong, X. Zou, K. Hinrichs, K. Calame, and S.P. Goff Inhibition of v-Abl transformation by p53 and p19ARF Oncogene 18 1999 7731 7739
125. A. Radfar, I. Unnikrishnan, H.W. Lee, R.A. DePinho, and N. Rosenberg p19(Arf) induces p53-dependent apoptosis during abelson virus-mediated pre-B cell transformation Proc. Natl. Acad. Sci. USA 95 1998 13194 13199
126. E. Nagy, Z. Beck, A. Kiss, E. Csoma, B. Telek, J. Konya, E. Olah, K. Rak, and F.D. Toth Frequent methylation of p16INK4A and p14ARF genes implicated in the evolution of chronic myeloid leukaemia from its chronic to accelerated phase Eur. J. Cancer 39 2003 2298 2305
127. R. Trotta, T. Vignudelli, O. Candini, R.V. Intine, L. Pecorari, C. Guerzoni, G. Santilli, M.W. Byrom, S. Goldoni, L.P. Ford, M.A. Caligiuri, R.J. Maraia, D. Perrotti, and B. Calabretta BCR/ABL activates mdm2 mRNA translation via the La antigen Cancer Cell 3 2003 145 160
128. A.W. Goetz, H. van der Kuip, R. Maya, M. Oren, and W.E. Aulitzky Requirement for Mdm2 in the survival effects of Bcr-Abl and interleukin 3 in hematopoietic cells Cancer Res. 61 2001 7635 7641
129. M.W. Deininger, J.M. Goldman, and J.V. Melo The molecular biology of chronic myeloid leukemia Blood 96 2000 3343 3356
130. C.L. Sawyers Signal transduction pathways involved in BCR-ABL transformation Baillieres Clin. Haematol. 10 1997 223 231
131. T. Skorski BCR/ABL regulates response to DNA damage: the role in resistance to genotoxic treatment and in genomic instability Oncogene 21 2002 8591 8604
132. C.L. Sawyers, A. Hochhaus, E. Feldman, J.M. Goldman, C.B. Miller, O.G. Ottmann, C.A. Schiffer, M. Talpaz, F. Guilhot, M.W. Deininger, T. Fischer, S.G. O'Brien, R.M. Stone, C.B. Gambacorti-Passerini, N.H. Russell, J.J. Reiffers, T.C. Shea, B. Chapuis, S. Coutre, S. Tura, E. Morra, R.A. Larson, A. Saven, C. Peschel, A. Gratwohl, F. Mandelli, M. Ben-Am, I. Gathmann, R. Capdeville, R.L. Paquette, and B.J. Druker Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study Blood 99 2002 3530 3539
133. M. Talpaz, R.T. Silver, B.J. Druker, J.M. Goldman, C. Gambacorti-Passerini, F. Guilhot, C.A. Schiffer, T. Fischer, M.W. Deininger, A.L. Lennard, A. Hochhaus, O.G. Ottmann, A. Gratwohl, M. Baccarani, R. Stone, S. Tura, F.X. Mahon, S. Fernandes-Reese, I. Gathmann, R. Capdeville, H.M. Kantarjian, and C.L. Sawyers Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study Blood 99 2002 1928 1937